Sugi Predict

Sugi Predict / Compounds / SCHEMBL1046464

SCHEMBL1046464

SCHEMBL1046464

O=c1[nH]c2cnc3ccccc3c2[nH]1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CDK4 P11802 1/20 0.44
▸ CCND1 P24385 1/20 0.44
▸ CA12 O43570 2/20 0.44
▸ PARP1 P09874 2/20 0.44
▸ CA9 Q16790 2/20 0.44
▸ KDM4E B2RXH2 2/20 0.44
▸ SIRT2 Q8IXJ6 1/20 0.44
▸ GABRA1 P14867 3/20 0.43
▸ GABRG2 P18507 3/20 0.43
▸ GABRB3 P28472 3/20 0.43
▸ GABRA5 P31644 3/20 0.43
▸ GABRA3 P34903 3/20 0.43
▸ GABRA2 P47869 3/20 0.43
▸ GABRA6 Q16445 2/20 0.43
▸ HDAC6 Q9UBN7 1/20 0.43
▸ PDPK1 O15530 1/20 0.42
▸ ALOX15 P16050 1/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ TNKS2 Q9H2K2 1/20 0.42
▸ GPR3 P46089 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Maleic Acid SCHEMBL18894353 0.88 MAPT (0.41) CDK4CCND1SIRT2GABRA1GABRG2
Fumaric Acid SCHEMBL18894354 0.88 MAPT (0.41) CDK4CCND1SIRT2GABRA1GABRG2
Trifluoroacetic Acid SCHEMBL30030258 0.87 DYRK1A (0.41) CDK4CCND1PARP1SIRT2GABRA1
SCHEMBL2021911 0.81 PARP1 (0.47) CDK4CCND1CA12PARP1CA9
Hydrochloric Acid SCHEMBL3396558 0.79 PARP1 (0.46) CDK4CCND1CA12PARP1CA9
SCHEMBL203094 0.79 KDM4E (0.51) CDK4CCND1KDM4ESIRT2GABRA1
SCHEMBL660137 0.77 MAPT (0.50) CDK4CCND1CA12PARP1CA9
SCHEMBL16748364 0.77 GABRA1 (0.50) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL3344660 0.76 PARP1 (0.39) CDK4CCND1PARP1KDM4EGABRA1
SCHEMBL30846772 0.76 PARP1 (0.42) CDK4CCND1CA12PARP1CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 627 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230173059-A1 TOLL-LIKE RECEPTOR (TLR) AGONIST NANOPARTICLES AND USES THEREOF THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2023-06-08 — — US claimed
EP-3442529-A1 COMBINATION THERAPY WITH NOTCH AND CDK4/6 INHIBITORS FOR THE TREATMENT OF CANCER Eli Lilly and Company (US) 2019-02-20 — — EP claimed
WO-2017180389-A1 COMBINATION THERAPY WITH NOTCH AND CDK4/6 INHIBITORS FOR THE TREATMENT OF CANCER ELI LILLY AND COMPANY (US) 2017-10-19 — — WO claimed
WO-2016186453-A1 QUINOLINE DERIVATIVES AS BROMODOMAIN INHIBITORS KAINOS MEDICINE, INC. (KR) 2016-11-24 — — WO claimed
EP-2648733-A1 SUBSTITUTED IMIDAZOQUINOLINE DERIVATIVES Piramal Enterprises Limited (IN) 2013-10-16 — — EP claimed
WO-2012077031-A1 SUBSTITUTED IMIDAZOQUINOLINE DERIVATIVES PIRAMAL LIFE SCIENCES LIMITED (IN) 2012-06-14 — — WO claimed
EP-2438064-A1 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES Novartis AG (CH) 2012-04-11 — — EP claimed
WO-2010139731-A1 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES NOVARTIS AG (CH) 2010-12-09 — — WO claimed
EP-1888578-A2 IMIDAZOQUINOLINES AS LIPID KINASE INHIBITORS Novartis AG (CH) 2008-02-20 — — EP claimed
WO-2006122806-A2 1,3-DIHYDRO-IMIDAZO [4,5-C] QUINOLIN-2-ONES AS LIPID KINASE INHIBITORS NOVARTIS AG (CH) 2006-11-23 — — WO claimed
EP-4683909-A2 ATM KINASE INHIBITORS Eberhard Karls Universität Tübingen (DE) 2026-01-28 — — EP disclosed
US-20260015328-A1 ATM KINASE INHIBITORS EBERHARD KARLS UNIVERSITÄT TÜBINGEN (DE) 2026-01-15 — — US disclosed
US-12344604-B2 Imidazolonylquinoline compounds and therapeutic uses thereof MERCK PATENT GMBH (DE) 2025-07-01 — — US disclosed
CN-119925616-A CD20 therapy, CD22 therapy and combination therapy with CD19 Chimeric Antigen Receptor (CAR) expressing cells 诺华股份有限公司 2025-05-06 — — CN disclosed
CN-119661531-A Imidazolone compound as well as preparation method and application thereof 北京富龙康泰生物技术有限公司 2025-03-21 — — CN disclosed
EP-0145340-B1 1H-Imidazo[4,5-c]quinolines and 1H-imidazo[4,5-c]quinolin-4-amines RIKER LABORATORIES, INC. (US) 1990-01-24 — — EP disclosed
EP-0310950-A1 Quinoline intermediates for the synthesis of 1H-imidazo[4,5-c]quinolines and 1H-imidazo[4,5-c]quinolin-4-amimes RIKER LABORATORIES, INC. (US) 1989-04-12 — — EP disclosed
US-4698348-A 1H-imidazo[4,5-c]quinolines and their use as bronchodilating agents RIKER LABORATORIES, INC. (US) 1987-10-06 — — US disclosed
US-4689338-A 1H-Imidazo[4,5-c]quinolin-4-amines and antiviral use RIKER LABORATORIES, INC. (US) 1987-08-25 — — US disclosed
EP-0145340-A2 1H-Imidazo[4,5-c]quinolines and 1H-imidazo[4,5-c]quinolin-4-amines RIKER LABORATORIES, INC. (US) 1985-06-19 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12344604-B2 Imidazolonylquinoline compounds and therapeutic uses thereof ATM, CHEK2, ATR CDK4 184/4885CCND1 2266/4885CA12 4819/4885
US-20230173059-A1 TOLL-LIKE RECEPTOR (TLR) AGONIST NANOPARTICLES AND USES THEREOF TLR3, TLR9, TLR1 CDK4 2389/4885CCND1 3160/4885CA12 2519/4885
US-20260015328-A1 ATM KINASE INHIBITORS ATM, CHEK2, CHEK1 CDK4 435/4885CCND1 1528/4885CA12 4699/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.